Aarti Drugs (NSE:AARTIDRUGS) Cash Flow from Discontinued Operations: ₹0 Mil (TTM As of Mar. 2026)


NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
75 GF Score
Price ₹375.30
GF Value ₹496.79
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs Cash Flow from Discontinued Operations?

Aarti Drugs NSE:AARTIDRUGS -0.29% 75 Cash Flow from Discontinued Operations is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 75/100 and a GF Value™ of ₹496.79 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Aarti Drugs's cash flow from discontinued operations for the three months ended in Mar. 2026 was ₹0 Mil. It means Aarti Drugs received ₹0 Mil from the sale of part of business quarterly. Aarti Drugs's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Aarti Drugs Cash Flow from Discontinued Operations Related Terms

Aarti Drugs Cash Flow from Discontinued Operations Historical Data

* Premium members only.

The historical data trend for Aarti Drugs's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Drugs Cash Flow from Discontinued Operations Chart

Aarti Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aarti Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:AARTIDRUGS
75GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
Cash Flow from Discontinued Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Drugs Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Discontinued Operations of ₹0 Mil mean?
Aarti Drugs (NSE:AARTIDRUGS) has a Cash Flow from Discontinued Operations of ₹0 Mil as of Mar. 2026. Cash Flow from Discontinued Operations is the amount of cash earned from ceased operations. View historical data for Apple Inc and its Aarti Drugs.
Is Aarti Drugs' Cash Flow from Discontinued Operations too high?
Aarti Drugs' current Cash Flow from Discontinued Operations is ₹0 Mil. Overall, Aarti Drugs has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' Cash Flow from Discontinued Operations compare to ZTS?
Aarti Drugs' Cash Flow from Discontinued Operations of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Discontinued Operations for a Drug Manufacturers company?
A good Cash Flow from Discontinued Operations depends on the Drug Manufacturers industry context. However, Cash Flow from Discontinued Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Discontinued Operations mean?
A high Cash Flow from Discontinued Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Discontinued Operations is the amount of cash earned from ceased operations. View historical data for Apple Inc and its Aarti Drugs. Aarti Drugs's current Cash Flow from Discontinued Operations is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹496.79, compared to a current price of ₹375.30 — trading 24.5% below its estimated fair value. The current Cash Flow from Discontinued Operations is ₹0 Mil. Aarti Drugs' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Discontinued Operations calculated?
Cash Flow from Discontinued Operations is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current Cash Flow from Discontinued Operations is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹375.30 is trading 24.5% below its estimated GF Value™ of ₹496.79. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • Cash Flow from Discontinued Operations: ₹0 Mil
  • GF Value™: ₹496.79 vs. price of ₹375.30 (24.5% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
75GF Score

Get the complete analysis for NSE:AARTIDRUGS

Cash Flow from Discontinued Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹375.30
Price
₹496.79
GF Value